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1. Introduction 
Millions of people all round the world suffer from various autoimmune disorders. T1D, MS, 
SLE, autoimmune diseases of the heart, liver, intestine and other internal organs, etc., all 
represent severe manifestations, which deteriorate the quality of life and cause physical 
disability and even death in patients with chronic illnesses. Every year, the largest world 
economies incur megabuck losses associated with medical services, insurance and drug 
procurement, not to mention the ever decreasing size of the able-bodied population. The 
development of preclinical diagnostic algorithms for autoimmune diseases, their 
implementation and introduction into routine clinical practice will help detect tissue or 
organ pathologies at the stages where their reversal is still possible. Early implementation of 
causal therapy allows the physician to compensate for the lack of one or another organ and 
ensures complete recovery or significant improvement of the patient’s health status. 
However, in developing updated preventive protocols, the investigator is faced with a 
necessity to solve fundamental problems in order to understand: 
 Who should be selected for examination? 
 What exactly needs to be checked? 
 When should the examination be performed? 
 And, last but not least, what are the analytical procedures for mass-scale monitoring? 
While constructing preclinical monitoring algorithms, one should also take into 
consideration the diseases suffered by patients’ relatives. One of the cornerstones in 
preventive and predictive medicine is screening for genetic abnormalities or hereditary 
predisposition. All-encompassing analysis of gene units and construction of individual 
genetic maps not only facilitate the assessment of individual risks for each concrete patient, 
but also allows prediction of disease development in first-degree-relatives. Therefore, 
today’s objective demands include not only large-scale monitoring of definite cohorts of the 
general population, but, rather, identification of high risk cohorts coupled with genetic 
abnormalities and/or shifts and social factors (residence, place of employment, occupation, 
living conditions, etc.). However, even a comprehensive analysis is inadequate without a set 
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of criteria providing high accuracy and reliability of state-of-health data. By illustration, it 
has long been believed that the same gene loci are specific for definite diseases including 
integer disease-related clusters. T1D, celiac disease, rheumatoid arthritis, multiple sclerosis, 
etc., they exist in close linkage with one another and often form polyglandular syndromes. 
Being a positively provisional discipline, genetics provides a fairly accurate prognosis for an 
individual; however, genetic tributes cannot always be adequately understood by reason of 
their ability to provoke extremely severe diseases. It should be taken into consideration that 
deleterious environmental (exogenous or endogenous) factors may strongly destabilize the 
physiological status of the organism by triggering pathological processes even in the 
presence of protective genes, and vice versa.  
Therefore, screening of patients for the presence and evolution of biomarkers should be 
included into all preventive medicine protocols alongside with the patient’s individual 
genetic map.  
Even an unambiguous allocation of patients into risk groups, selection of basic state-of-art 
(additional, individual, etc.) screening criteria and personalized approaches to every new 
patient will hardly be successful without selection of optimal conditions and methods for 
obtaining reliable and reproducible clinical data on a mass scale.  
The practical realization of these principles will enable the physician to diagnose 
abnormalities and/or disorders at the very earliest stages and to predict their outcome. 
However, suspension or blockade of pathological processes presents a formidable challenge 
to the medical community. In designing therapeutic strategies for autoimmune diseases, two 
important issues, namely, targets for autoimmune attacks and depth of morphofunctional 
deficiency of an organ or a tissue, should be taken into consideration. The first issue is more 
or less clear, since immunosuppressors with specific or nonspecific activities have long been 
used in the clinical practice, while the second one is not so apparent. Restoration of the 
structure and function of affected tissues can successfully be achieved through practical 
realization of the following strategies:  
 allogeneic or xenogeneic transplantation. The main challenges include high risk of so-
called “graft-versus-host” responses and rejection of transplanted tissues (graft 
rejection); 
 medical products with regenerative resources. This technology seems to hold especially 
great promise in modern medicine. Some medicinal drugs (e.g., IgM for MS) are widely 
employed in the clinical practice, while others (e.g., peptide-based drugs for MS, 
rheumatoid arthritis, T1D) are under intensive development. The main obstacles on the 
way to large-scale application of such drugs are low efficiency, particularly due to 
organism’s addiction to their active substances (reduced number of receptors, 
downregulation, etc.), and hyperactivation of the excretory system (augmented 
synthesis of liver microsomal enzymes, hyperexcretion with urine, faeces or sweat, etc.); 
 stem cell technology. This trend is especially actively debated by the medical 
community because of its high relevance to ethic problems and legal prohibitions, on 
the one hand, and inability to maintain “stemness” for sufficiently long periods of time 
and differentiation of stem cells into “undesirable” pools, on the other. Similar 
problems arise at virtually every stage, viz.: search for and isolation of stem cells from 
the organism; enhanced accumulation of biological material, which may be critical 
under conditions of fulminant progression of the disease and pronounced deficit of 
time; necessity to maintain the pluripotent state of cells for sufficiently long periods of 
time without malignization in vitro; delivery of SC; provisional differentiation and 
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acquisition of high-quality material in vitro and control over differentiation into desired 
cellular pools in vivo. 
Taking into consideration the foregoing and being guided by the Major Preventive and 
Preventive Medicine Principle, we developed an original protocol for screening and 
postscreening management of patients, which includes: 
Comprehensive genetic analysis for estimating potential risks for patient’s (or his/her 
relatives’) individuality and design of protocols for diagnostic assessment and preventive 
treatment;  
Proteomic analysis and detection of metabolic shifts including identification of biomarkers 
(e.g., autoAbs in case of autoimmune disorders); monitoring of evolutional and spectral 
characteristics of biomarkers; control over emergence of new biomarkers for updating 
prophylactic and preventive treatment protocols and maintenance of high curability 
standards;  
Persistent control over predisposing factors including identification of factors potentiating 
specific pathologies (analysis of bacterial and virus-borne infections, monitoring compliance 
with regimen and other preventive measures, etc.); 
Psychologic doctor-patient cooperation, strict compliance with doctor’s recommendations 
and requirements through elucidation of disease severity (including the preclinical stage).  
The use of advanced screening strategies and early implementation of specific therapy 
ensure substantial reduction of morbidity and mortality from autoimmune disorders and, as 
a consequence, significant improvement of life quality and minimization of economic losses. 
The same principles are embodied in the guidelines of preventive and predictive medicine. 
Their practical realization may culminate in the establishment of an international research 
network, development of novel criteria for preclinical diagnosis and treatment and 
validation of uniform specifications and standards for laboratory diagnostics.  
2. The preclinical diagnosis algorithm and a new conceptual model of T1D 
etiology 
T1D is an autoimmune disease induced by a vast variety of triggering factors. In individuals 
with genetic predisposition to T1D, these factors initiate autoimmune processes culminating 
in the appearance of autoAbs and infiltration of the pancreas with self-reactive T cells. In its 
turn, progressive deterioration of pancreatic functional activity leads to systemic metabolic 
and immune failures. These processes show a tendency for self-acceleration, aggravation by 
associated diseases or numerous adverse factors and formation of new linkages between 
immunoregulatory and immunoeffector compartments within the immune system. T1D is 
also distinguished for alterations at the cellular level including pathological changes in cell 
to-cell interactions, incompatibility of packages of secreted humoral factors, and so on. 
Intracellular events provoked by specific uncongenial conditions in the cell environment 
also play a role. Therefore, humoral factors secreted at any (cellular, tissue or organic) level 
and pathological changes in any link of the metabolic cascade can be regarded as highly 
specific biopredictors and valuable tools for preclinical diagnosis of T1D. 
In the course of the autoimmune process, T1D goes through a number of sequential stages, 
which differ from one another by the degree of severity of the underlying pathology, 
functional peculiarities of affected organs and clinical manifestations of the disease. A 
personalized therapeutic approach must be based on a detailed analysis of the immune status 
with special reference to the patient’s genetic map and is prerequisite to the construction of 
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any early diagnosis protocol designed to indicate the pathology, to identify the stage of the 
autoimmune process and the functional status of the target organ and to develop, on their 
basis, a strictly individual treatment schedule. In addition, this approach entails early 
implementation of pharmacocorrective therapy and prediction of scenarios for disease 
progression. (Suchkov et al., 2010) 
In order to follow the dynamics of T1D on the time scale and to estimate efficiency and 
sensitivity of innovative approaches to preclinical diagnosis, we developed a fundamentally 
new strategy of pathogenesis. Its major goal is crucial features of the disease with special 
emphasis on its diagnosis allowing the physician to implement adequate preventive therapy, 
to prolong the preclinical stage and to delay clinical manifestations of the disease. 
Stage I is often defined as the “genetic predisposition” step. Its most salient feature is a 
repertoire of predisposition genes (predominantly, MHC class II) responsible for 
susceptibility to autoimmune diseases and direct initiation, gradation and exacerbation of 
immune pathologies.  
Stage II is often referred to as the “intervention” step. At this stage, provoking exogenous or 
endogenous factors interfere with the normal functioning of immune mechanisms and 
deplete the functional reserves of the affected organs providing the formation of the 
autoimmune status (e.g., postinfective autoimmune syndrome).  
Stage III represents an “ignoring” step where progressive disturbances in immune 
homeostasis are unaccompanied by direct attacks at target organs. Clinical manifestations of 
T1D and visible lesions in the pancreas architectonics are absent in this step, while the 
functional activity of the pancreatic gland is unimpaired. AutoAbs are either not produced 
or their titers are negligibly small. 
Stage IV is characterized by termination of the ignoring step and initiation of autoimmune 
processes. The main participants at this stage are molecular factors (e.g., addressins) 
triggering autoimmune reactions specifically directed against islet cells. At this particular 
level, clonal ignoring collapses and organ infiltration occur. 
Stage V is closely associated with the development of immunological disorders. Its central 
event is generation of autoAbs to insulin, GAD, ǃ-cells, heat shock protein 60 (hsp60), zinc 
transporter and fogrin. AutoAbs can be specific against a single antigen (Ag) or several Ags.  
Stage VI is defined as a “transition from uncontrolled violence to chaos”. Here, minor 
systemic failures related to immunological disregulation progress to the extent of profound 
disorders. Clinical symptoms are still missing at this stage, but latent tolerance to glucose 
develops.  
Stage VII. This “complete overall imbalance” step occurs when ǃ-cell destruction reaches a 
certain critical level (80%). This stage is characterized by hyperglucosemia and insufficient 
production of insulin. Metabolic processes fluctuate slightly within normal limits due to 
residual secretion of the C-peptide. 
Stage VIII, often referred to not as a T1D stage, but, rather, as emerging complications, is 
defined as “total or genuine diabetes”, since beta cell destruction is fully complete in this 
step. It is distinguished for steadily decreasing titers or complete disappearance of autoAbs, 
functional failure of the pancreas, high glucosemia and glycosylation of proteins (including 
hemoglobin) against the background of systemic hypoxia and metabolic collapse. Other 
manifestations include disturbances in water-salt metabolism, osmotic diuresis, 
dehydration, activation and acceleration of gluconeogenesis and ketogenesis, enhanced 
breakdown of proteins and lipids, impaired lipid metabolism (low HDL levels and high 
LDL levels) and elevation of osmotic blood pressure resulting in microvascular and nerve 
www.intechopen.com
Preclinical and Predictive Algorithms in Monitoring  
Patients with Autoimmune Diseases and Their Relatives-at-Risks 
 
195 
tissue injuries. These disturbances are usually concomitant with acute manifestations (coma) 
or form the basis for more distant pathologies (micro- and macroangiopathies, neuropathies, 
ophthalmopathies, nephropathies, etc.).  
 
 
Fig. 1. The pathogenesis of T1D. Genetic and environmental factors are key elements in the 
susceptibility to T1D. Susceptible individuals develop autoimmune insulitis, which is 
mediated by CTL against autoAgs of beta cells and is characterized by enhanced production 
of a vast array of antiinflammatory cytokins and free radicals triggering the death 
(apoptosis) of beta cells as main targets in inflammation. 
The first five stages are defined as preclinical pathology stages, while Stage VI is thought to 
represent a transient step. It is diagnosing T1D at stages I – V and the use of preventive 
treatment protocols that enable the physician to delay the progression of the underlying 
disease and to procure complete recovery. (Antonio Gonzalez at. al., 1996s; Matthias von 
Herrath at al., 2007) 
3. The origin of genetic predisposition or “genomics: A base of preclinical 
medicine” 
Our knowledge of pathological processes occurring in the human organism has progressed 
considerably in the past decades, but the mechanisms of many human diseases are still 
poorly understood. Recent developments in genomics made it possible to discover a wide 
variety of novel genes and genetic variations including clinically important ones. i.e., those 
triggering pathological processes in various body tissues and cells. Every year, the clinical 
diagnostic instrumentarium is supplemented with efficient analytical techniques for 
detecting single-nucleotide polymorphisms (SNP’s) which determine the susceptibility of 
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the organism to diseases, drugs and/or environmental factors. A deeper insight into gene 
structure and regulatory mechanisms can significantly facilitate diagnosis and treatment of 
individuals at risk and, in a more distant future, provide the physician with potent tools for 
diagnosing diseases, preventing their progression and implementing effective therapy as 
early as the preclinical stage.  
Rapid progress in science and technology created necessary prerequisites for high-
throughput screening of several hundreds of thousands of SNP variants and enabled 
adequate involvement of all human DNA blocks in selection of the disease associated 
variant provided the latter is present in the genome. From theoretical standpoint, linking of 
genotyping data to epidemiological findings provides a way to identification and/or 
characterization of gene sequences and gene interactions with the environment determining 
the susceptibility of various body cells and tissues to normal genetic variations and/or the 
underlying disease. 
Genomewide association studies represent an effective tool for detecting genetic 
associations between specific genetic variations and complex pathological conditions in 
large cohorts of the general population and provides a deeper insight into mechanisms 
underlying genetic predisposition to various diseases.  
The contribution of SNP’s to the pathogenesis of many common diseases is relatively small 
and does not exceed 5–10%, which significantly restricts their application as markers for 
predicting disease risks. However, today well-established associations number in hundreds 
and their panel grows with every passing week. Taking into account considerable 
investments in the search for hitherto unidentified sources of inherited risks, it may be 
expected that existing (both genomic and nongenomic) models for estimating potential risks 
will soon be improved and rationalized. 
The current need for highly multiplexed tests increases with every passing day. Innovative 
gene chip- and sequencing-based technologies displace rapidly traditional methods for 
establishing variations and mutations in the human genome. In future, the advent of 
improved nanotechnological sequencing protocols may further increase the accuracy and 
reduce the cost of genetic analysis. The idea of complete sequencing of the human genome 
at the cost of $1000 is becoming more and more realistic. The project, which got the name 
“$1000 genome”, is expected to improve existing protocols through direct sequencing of 
individual DNA molecules. This approach is potentially oriented at elimination of the 
amplification step, further reduction of chemical reagents expenditure and construction of a 
high-precision database of genetic sequences in the foreseeable future.  
The feasibility of reliable and low-cost estimation of human genetic variations put forward 
the idea of personalized medicine as an indispensable element of modern-day public health 
care. The key principle of personalized medicine is in that the health status of any human 
individual is most effectively controlled through implementation of individual preventive 
and curative treatment schedules. Although unsolvable controversies between principles of 
personalized medicine and populational (probative) medicine really exist, they are not 
inconsistent. Novel decisions are being taken in the private and public sectors, and those 
would enable progressive studies to provide the linkage between personalized and 
probative medicine.  
All-round cognition of gene structure and genetic regulatory mechanisms is extremely 
important not only from theoretical, but also from practical point of view, particularly, for 
www.intechopen.com
Preclinical and Predictive Algorithms in Monitoring  
Patients with Autoimmune Diseases and Their Relatives-at-Risks 
 
197 
the development of state-of-art diagnostic, prognostic, preventive and therapeutic strategies 
for treatment of rarely occurring and common diseases. 
3.1 IDDM1 as an example of crucial role of genomics in clinical researches  
The use of high-throughput technologies in human genome studies was a step forward 
towards getting a deeper insight into pathogenetic mechanisms of many human diseases 
including insulin-dependent type 1 diabetes mellitus (T1D). Recent developments in the 
field of genetic factors and their pathogenetic roles suggest their high utility in the design of 
novel predictive strategies, stratification of patients according to disease risk and a search 
for new therapeutic targets. Among the immense variety of T1D strategies, two approaches 
are used methods of choice, viz.: (I) linkage studies of pairs of affected relatives (typically, 
siblings) aimed at a search for rarely occurring risk factors having large effective sizes; (II) 
association studies into more common risk factors having small effective sizes.  
3.2 MHC: Genes of instability 
As can be seen, identical genes can simultaneously trigger a variety of body-related 
autoimmune disorders. The latter form a disease-based cluster, which further develops into 
a polyglandular autoimmune syndrome. (Fernando MM et al., 2008) 
 
 
Fig. 2. The role of MHC genes in the development of diseases the key pathogenetic role in 
which is played by genetic predisposition. Some genes (DR7, DR8) determine the risk for 
only one disease (DR7, DR8), while others are responsible for two (DR1, DR10), three or 
even more (DR4) diseases. However, their presence is not prerequisite to the development 
of pathological processes, but, rather, significantly increases the likelihood of their early 
occurrence during the patient’s lifetime. 
MHC represents a large family of genes encoding molecules of three major HLA classes, 
viz., HLA class I, HLA class II and HLA class III. MHC plays an essential role in the 
functional activity of the immune system being directly involved in presentation of peptide 
antigens to APCs and formation of the so-called MHC restriction phenomenon. To-date, 
MHC is the most thoroughly investigated gene family in the human genome by virtue of its 
extremely close linkage to autoimmune diseases, hypersensitivity to infections and 
hyperbolic immune responsiveness. These genes are usually present in patients with severe 
autoimmune disorders and/or imbalances, e.g., rheumatoid arthritis (RA), multiple sclerosis 
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(MS), Crohn’s disease, aneurisms of large vessels (ALV), ulcerative colitis (UC), systemic 
lupus erythematosus (SLE) and type 1 diabetes (T1D).  
 
 
Fig. 3. The role of various MHC classes I, II and III alleles in the development of T1D. The x 
axis designates the continuous arrangement of some MHC 123 regions. The vertical graph 
segment indicates the association of an allele with a specific MHC region and the typical 
scatter of diabetogenicity probabilities for the given allele. 
3.3 HLA class I: Role in T1D 
Molecules of HLA class 1, jointly with HLA class II molecules and in closest association with 
one another afford effective protection against T1D and risks thereof. The HLA class I 
compartment contains both diabetoprotective genotypes (A*1101, A*3201, A*6601, B*0702, 
B*4403, B*3502, C*1601, C*0401) and highly associative genes (B*5701, B*3906). The 
diabetogenic alleles of MHC class I genes display age-related features. For example, HLA-
E*0101 is predominant in patients in whom T1D developed during the first 10 years of life, 
while HLA-E*0103 is found in children under 10. (Hodgkinson AD et al. 2000) Apart from 
borderline (diabetogenic or diabetoprotective) genes, there exist several intermediate types 
(A*2402, A*0201, B*1801, C*0501). All of them increase the risk of diabetes, but their role in 
triggering autoimmune responses is insignificant. (Noble JA et al., 2010) 
The increasing number of publications devoted to genes associated with T1D (Howson JM et al., 
2009; Viken MK et al., 2009) and identification of reactions stimulating or potentiating beta cell 
destruction testify to the fact that HLA class I initiate and potentiate autoimmune destruction of 
beta cells and manifest close linkage to HLA class II. (Lipponen K et al., 2010) Systemic 
autotolerance of homogeneic CD8(+) T cells is one of the patterns subject to regulatory control 
of HLA class I. It is well known that T1D is concomitant with disturbances in coordinated 
interactions between HLA-E CD8(+) T cells and HSP60sp that are specific to them. This 
phenomenon is responsible for disturbances in so-called “friend or foe” identification during a 
switchover of normal immune processes to self-destruction. (Jiang H et al. 2010) 
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Some methods for early diagnosis of T1D e.g., ex vivo detection of GAD65 autoreactive T cell 
CD8(+) by HLA class I tetramers, are based on the use of HLA class 1 I antigens. (Giuliani L 
et al. 2009) 
3.4 HLA class II: A wheelhorse or a time bomb? 
HLA class II constitute a family of genes localized on the short arm of the 6th chromosome. 
These genes encode glycoproteins with an Ig-like structure and are predominantly localized 
on the APCs surface. Their functional role consists in presentation of Ags peptides to 
CD4(+) T helper cells type I. There exist several autoimmune diseases (including T1D) 
supported by promoting effects of HLA class II Ags.  
Presumably, MHC glycoproteins modify positive and negative selection in the thymus 
allowing some immature autoAg-reactive T cells to escape from immune surveillance and 
thus avoid negative selection. However, presentation of morbid peptides to cytotoxic T 
lymphocytes (CTLs) or T helper cells by mature MHC seems to be more likely. Polymorphic 
variants (cytokin-related genes) residing in the vicinity of MHC classes I, II and III and non-
MHC significantly increase the predisposition to autoimmune diseases and impart high (in 
comparison with healthy individuals) genomic instability. When the cells switch over their 
modality from Ag expression to MHC class II production, the molecules localized on the cell 
surface begin to form potentially autoreactive complexes and thus provoke self-reactive 
immune responses. Such nondiscriminating Ags were identified on the surface of beta cells 
of patients with T1D, on thyroid cells of patients with Grave’s disease and on bile duct cells 
of patients with primary biliary cirrhosis. (Béatrice Faideau et al. 2005) 
 
 
Fig. 4. The distribution of diabetogenic and protective potentials of HLA class II in different 
racial populations. Green columns: low risk (diabetoprotective); yellow columns: medium 
risk (moderately diabetogenic); red columns: highly diabetogenic. The diabetogenicity of the 
same alleles in different populations is either similar or radically different. It is not excluded 
that this parameter is controlled by environment factors. 
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This bar chart displays the most important T1D-predetermining haplotypes and their 
distribution in different populations. As can be seen, the presence of the same haplotype in 
two different populations contributes differentially to T1D-associated risks. For example, in 
Russians DQA1*0301 elicits a nearly 85% risk of T1D, whereas in Latinos the risk is less than 
75%. Moreover, haplotypes spreading risks of diabetes in one population can be nonspecific 
for other populations. As regards DQA1*0301 its effect on acquisition of sensitivity to T1D is 
negligibly small in Brazilians, while in Chinese, Japanese, Arabians, Finns and Caucasians 
this haplotype is not associated with diabetes. These findings suggest that genetic features, 
haplotype frequency and contribution of specific haplotypes to susceptibility to T1D vary 
widely in different populations indicating different diabetogenic or protective orientation 
and high risk of T1D development. 
Analysis of specific domains of the human genome made it possible to establish their roles 
in pathological processes and to get a deeper insight into molecular mechanisms responsible 
for instability of the human biome. The clue to the practical solution of problems in this area 
is to discover novel genetic markers, to secure low cost of the analysis and to ensure high 
accuracy of the methods employed. The totality of these factors may culminate in the 
construction of unique tools for subclinical diagnosis and preventive medicine. 
3.5 HLA class III: Role in genetic predisposition 
Far fewer (compared to HLA classes I and II) messages deal with contribution of HLA class 
III to background predisposition to T1D. In constructing a basic screening algorithm with 
special reference to early diagnosis potentials, one should take into consideration the crucial 
role of this region’s genes in predisposition to T1D.  
There exist about a dozen HLA class III genes manifesting a diagnostically significant 
association with T1D. These include NOTCH4 (rs2395106) responsible for susceptibility to 
rheumatoid arthritis and MSH5 (rs707915) associated with a high risk of T1D. As an overall 
trend, HLA classes II and III provoke diabetes at the highest levels of the odds ratio, while 
the effect of HLA class I on T1D is much less expressed (see Figure 3). (Valdes AM et al. 
2006; Yamaji K et al.2006)  
3.6 Non-MHC genes and their contribution to T1D 
Any systemic approach to T1D diagnosis demands a large set of complementary and 
mutually specifying biomarkers. In addition to screening of circulating autoAbs and MHC 
Ags, systemic analysis of non-MHC genes is extremely important for validating the 
diagnosis. Though the odds ratios of the overwhelming majority of MHC genes are by one 
order of magnitude lower than that of MHC, identification of these gene clusters allows a 
qualitative description of risks for various autoimmune disorders including generation and 
progression of insulitis and, in a more distant perspective, objective prognosis of T1D 
outcomes.  
In all probability (and not too surprisingly), each individual gene does not act specifically 
upon every component of the immune system or cell metabolism, but, rather, exerts a 
complex action by forming a kind of a pathological system. An immense variety of genes 
responsible for susceptibility to T1D are known, but their functional capabilities are either 
obscure or poorly investigated. Some SNPs whose role in etiology and pathogenesis of T1D 
leaves no doubt are described below. (Barret et. al., 2009) 
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Fig. 5. A comparison of some diabetogenic non-HLA genes having mean values for HLA. 
The height of the column reflects the average probability of the clinical stage of type 1 
diabetes (IDDM1) for the given allele. at the same time, MHC genes manifest a high degree 
of variation and, in some special cases, diabetoprotective activity. 
TNFAIP3 (A20), tumor necrosis factor, alpha-induced protein 3. In the pancreas, this gene 
performs miscellaneous functions to include inactivation of NF-kappa B signals, prevention 
of inflammatory lesions of pancreatic cells, deceleration or delayed recruitment of 
immunocompetent cells into target organs, retardation of intercellular matrix restructuring, 
and so on. Studies by Liuwantara D et al. established that expression of the A20 gene is an 
effective mechanism of beta cell protection from TNF-induced apoptosis. Mutations in this 
gene and formation of SNPs initiate functional disturbances in NF-kappa B and represent 
the most common mechanism of disregulation and disorganization of immune reactions 
resulting in autoimmunity. Yet another salient feature of A20 is its ability to stimulate 
angiogenesis. Knockout of A20 shortens the tubule area and length in mice in vitro. (Grey ST 
et al., 2003) 
A crucial role in specification of APCs and pathogenesis of T1D is played by the ERBB3 
gene known under the official name “v-erb-b2 erythroblastic leukemia viral oncogen 
homolog 3 (avian)”. This gene encodes the family of specific receptors to the epidermal 
growth factor (EGFR).  
Mutations in ERBB3 lead to immunoregulatory collapses coupled with continuous 
emergence of autoreactive cells. By virtue of its ability to provide linkage between genetic 
predisposition, infectious diseases and adaptive immune reactions, ERBB3 has every right to 
be regarded as a central molecular constituent element of the T1D-inducing complex. 
(Hongjie Wang et al., 2010)  
PTPN22 (LYP), known under the official name “protein tyrosine phosphatase, non-receptor 
type 22 (lymphoid)”, encodes lymphoid-specific intracellular phosphatase able to bind to 
the molecular adaptor protein CBL and thus controls its activity in the signaling pathway of 
the T cell receptor (TCR).  
PTPN22 contains several SNPs disturbing normal operation of immune mechanisms. SNP 
rs2476601 is a valuable biomarker of susceptibility to autoimmune diseases, but its role in 
NK cell biology is not yet finally elucidated. The fact that SNP rs2476601 upsets the balance 
between T and NK cells in vitro points to the involvement of PTPN22 in immune regulation 
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of NK function. (Douroudis et al., 2010) The PTPN22 allele 1858T worsens the function of 
beta cells. 1858T is associated with IAA, an autoAb participating in pancreas destruction. 
The 1858TT and 1858CT genotypes exhibit a steadily increasing risk for the appearance of 
additional autoAbs and clinical manifestations of the disease. 
The primary mechanism of PTPN22 SNPs is launched upon triggering of insulin-specific 
autoimmune responses. SNPs produce multifarious effects: they disturb functional activity 
and suppress metabolic responses of beta cells to changing blood glucose levels, stimulate 
the transition from prediabetes to type 1 diabetes, and so on. (Fichna et al., 2010; Taniyama 
et al., 2010; Hermann et al., 2006) 
The IFIH1 gene (interferon induced by helicase C domain 1, also known as MDA5) encodes 
the DNA receptor associated with viral infections with a concomitant formation of 
autoreactive T cells and induction of autoimmune diabetes. Moreover, IFIH1 fulfils a 
protective function in hypomorphic expression of IFIH1. (Downes K et al., 2010) IFIH1 is 
directly involved in the destruction of Langerhans islets due to pooling and mobilization of 
autoreactive cells in response to viral invasion. This circumstance aggravates immune 
dissonance and promotes self-restructuring of targeted organs by provoking persistent 
deficiency of the pancreas and accelerating insulin failure. IFIH1 disturbs cell-mediated and 
humoral immunity by initiating selective deficiency of IgA. (Ferreira et al., 2010)   
IL2RA (interleukin 2 receptor, alpha, also known as CD25, T1D0, TGGFR) represents, along 
with IL2RB and the Ǆ-chain IL2RG, a fragment of the high-affinity receptor IL-2 
(homodimerization of ǂ-chains yields low-affinity receptors, while homodimerization of ǃ-
chains gives receptors with medium affinity). By virtue of its structural and functional 
peculiarities, IL2RA makes the greatest contribution to the progression of T1D. It regulates 
immune and inflammatory responses, exerts negative control over cell proliferation and 
favors differentiation of T cells. In addition, IL2RA controls apoptosis via a positive 
feedback mechanism. Mutations in the IL2RA gene point to IL2RA insufficiency. Genetic 
variations in IL2-IL21 and IL2RA/CD25 regions predetermine the susceptibility to T1D by 
interfering with the transcription and/or splicing of mRNA. In this way, IL2 and IL2RA 
exert genetic control over protein expression in different cell subpopulations. (Dendrou et 
al., 2008)  
The INS (ILPR, IRDN, IDDM2, MODY) gene is a key participant in the synthesis of insulin 
molecules. In patients with T1D, the mutation frequency of this gene does not exceed 0.1%. 
(Rajasalu et al., 2007)  
CD226 (rs763361) SNPs regulate the activity of certain cells involved in immune 
mechanisms mediating beta cell destruction. The susceptibility to T1D is associated with 
SNPs rs763361 (genotype TT, OR = 2.29) and allele T (OR = 1.48). (Douroudis et al., 2009; 
Hafler et al., 2009)  
In conclusion, we can state with assurance that nearly the overall repertoire of genes whose 
mutations are known to increase the risk of T1D development has been identified and 
characterized in terms of functional activity, which includes:  
 Protection of beta cells from apoptosis (TNFAIP3); 
 Secretion and metabolism of insulin (INS); 
 General immunity (ERBB3, IL2RA, PTPN22, PTPN2, SH2B3, CTLA4, SUMO, ICOS;, 
etc.); 
 Undefined function (CTSH, CLEC16A, IL7RA, CIQTNF6); 
 Generation of autoAbs to beta cells (mostly, in adults) (HLA-DR3); 
 Generation of autoAbs to insulin and formation of the insulin resistance syndrome 
(mostly, in adolescents)(HLA-DR4); 
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 Supporting high risks of autoimmune processes (HLA-DQ-related T1D) (NB: HLA-
DR3-DQ2 and HLA-DR4-DQ8 genes are among the most popular T1D inducers in 
young children); 
 Diabetoprotective function (HLA-DR2, DR6, DR7) (NB: HLA-DR1, DR5, DR8 and DR9 
genes are usually identified in individuals for whom T1D is uncommon). 
From the foregoing it follows that the first step of preclinical diagnosis must include 
identification of classical genetic biomarkers for each concrete pathology and acquisition of 
information from three basic resources: (i) genealogic tree, (ii) anamnesis morbid and (iii) 
anamnesis vita. 
This approach would enable identification of individuals predisposed to a concrete disease 
and their distribution into risk groups with further transition to the second stage where 
patients are subject to investigation, using target panels of genotypic and phenotypic 
biomarkers and continuous monitoring of potentially affected cohorts and those 
predisposed to the preclinical pathology stage. The primary testing approach demands 
validated procedures for detecting molecular and cellular shifts in one or another cell 
and/or tissue function in the paradigm of the most pathogenetically significant targets. The 
methods employed thereupon include high-performance genomic and metagenomic 
scanning as well as proteomic and metabolic analyses in the paradigm of microbial colony-
forming populations. Moreover, biomonitoring is based on the use of a vast array of 
nanotools as well as visualization and biosensoric facilities allowing comprehensive 
examination of “suspected” individuals and elaboration of wide-range activity-oriented 
treatment schedules in a real-time mode.  
4. Proteomics: A powerful tool for predictive medicine 
The role of proteomic technologies in the study of autoimmune diseases can hardly be 
overestimated. Virtually all currently known autoimmune diseases including diabetes 
mellitus, multiple sclerosis, systemic lupus erythematosus and other severe autoimmune 
disorders have proteomic markers of their own. At the same time, the advent of efficient 
high-precision diagnostic technologies opened up new opportunities in the search for novel 
preclinical diagnostic markers. Identification of autoAbs to immunoglobulins GADA, IAA, 
ICA, IA-2A and ZnT8 has become a routine procedure in T1D diagnosis. In this chapter, the 
main emphasis will be laid on some characteristics of specific proteins for progressive T1D. 
Clusterin (apolipoprotein J) holds considerable promise as a candidate biomarker; its main 
function is traditionally recognized as a tool to control apoptosis. It should be noted, 
however, that clusterin exhibits the behaviour of an antiapoptotic chaperone when used at 
low concentrations; at higher concentrations ( 12% of control), it causes disruption of 
mitochondria and initiates cell apoptosis by a mitochondrial mechanism. Recent reports 
highlighted a high regenerative potential of Clusterin, particularly, with respect to beta cells. 
The functional activity of this protein demands further verification and analysis, but its 
elevation always points to apoptosis of pancreatic beta cells. (Lee et al., 2011)  
Transcortin (Corticosteroid-binding globulin, CBG) and Lumican are capable to induce 
pronounced (1.5–2-fold against control) upregulation. Transcortin fulfils the function of a 
glucocorticoid transporter and is strongly inhibited by insulin; hence, insulin deficiency is 
always associated with hyperproduction of Transcortin. (Fernández-Real et al., 1999) 
However, this protein is hardly effective as a selective biomarker for T1D, since it emerges 
exclusively at the latest stages of autoimmune aggression and its role in T1D etiogenesis is 
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still unclear. Lumican, the key mediator in fibrosis-related processes, manifests an even 
higher degree of upregulation than Transcortin and is widely distributed in all body tissues. 
Its significant elevation may represent an acute response of renal tissues to high plasma 
levels of glucose and is also characteristic of nephropathies. However, being a convenient 
tool for predicting diabetic nephropathies, Lumican cannot predict associated diseases. 
It may be concluded from the above-said that Clusterin is the only candidate for a selective 
protein biomarker for T1D, because it emerges at early stages of the disease and is more 
related to cause than effect.  
5. Effects of autoAbs on the launch of autoimmune processes and pancreas 
deficiency: Dynamics of spectra and prognostic value in preclinical 
diagnosis of T1D 
Today, autoantibodies (autoAbs) are the main biomarkers of diabetes mellitus. The presence 
of small concentrations of autoAbs in peripheral blood does not always indicate initiation of 
an autoimmune process, because the organism possesses a vast number of autoregulatory 
mechanisms. However, their collapse and significant elevation of Ab titers indicate a nearly 
100% risk for diabetes in the foreseeable future. Many autoAb classes are currently known 
including GADA (65 and 67), IA-2Ab, INSab, HSPab, ZnT8ab, IAA, etc. 
Each of these autoAbs has a prognostic value of its own and is associated with a definite 
type of diabetes (T1D, latent diabetes, fulminant diabetes, etc.). The factors initiating the 
appearance of autoAbs are also different. Among the immense diversity of causative factors, 
diabetogenic genes (classes I, II and III MHC) responding by activation to virus-induced 
inflammation (molecular mimicry) are of paramount importance. The results of in-depth 
studies on associativity between MHC II alleles and auto-Abs unequivocally suggest that in 
the present state of the problem generation of certain classes of auto-Abs and further 
progression of T1D can be predicted on the basis of genetic data even at the earliest stages of 
the disease.  
5.1 GADA 
Glutamate decarboxylase catalyzes the conversion of glutamic acid into Ǆ-aminobutyric acid 
and CO2 and plays a prominent role in the functional activity of the central nervous system 
(CNS). Its substrate (glutamic acid) is responsible for excitation, while its major metabolic 
product (Ǆ-aminobutyric acid) is a key mediator of inhibition in brain neurons. The 
physiological role of this enzyme is confined to various aspects of insulin-dependent 
diabetes. 
Two isoforms of GAD (GAD65 and GAD67) are encoded by two non-allelic genes localized 
on different chromosomes, more specifically, on the 2nd (GAD65) and 10th (GAD67) 
chromosomes. Both isoforms are actively expressed in CNS neurons. In human islet cells, 
GAD65 is a predominant isoform, while GAD67 is either present in negligibly small 
amounts or is not expressed at all. In contrast, in rat islet cells both GAD isoforms are 
expressed with a nearly equal efficiency, but the GAD67 isoform is predominant. 
The prognostic significance of GADA is rather high. These autoAbs appear in circulating 
blood before other auto-Abs ( 10 – 15 years before the appearance of first clinical 
manifestations of T1D) and are detected in 70 – 90% of cases.  
Risks for T1D and Ab titers 
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Autoantibody titer 10-year risk (% ± SE) HR (95% CI) P 
I quartile   35 ± 9 1*  
II quartile   22 ± 9 0.8 (0.3–1.9) 0.55 
III quartile   52 ± 9 1.7 (0.8–3.6) 0.18 
IV quartile   43 ± 10 1.6 (0.7–3.6) 0.26 
Likelihood of developing diabetes depending on the combination of epitope-specific GADA 
antibodies 
 
GADA 
Epitope combination n (T1D cases) 10-year risk 
MID COOH NH2 67  
+ + + + 24 (8) 39%
+ + + − 12 (6) 26%
+ + − + 15 (5) 56%
+ + − − 62 (21) 45%
+ − + − 1 (0) 
+ − − − 13 (3) 27%
− + + + 1 (0) 
− + − − 5 (2) 48%
− − + − 6 (1) 20%
− − − − 10 (3) 33%
For GAD antibodies, MID refers to epitopes within GAD65 amino acids 235–442, COOH 
refers to epitopes within GAD65 amino acids 436–585, NH2 refers to epitopes within GAD65 
amino acids 1–100, while GAD67 refers to epitopes present in GAD6 (combinations with no 
relatives are not shown). (Buzzetti et al., 2007; Mayr et al., 2007)  
5.2 IA-2 
IA-2 belongs to type 1 membrane-bound proteins containing extracellular NH2-terminal 
glycosylated, membrane-bound and СǼǼǻ-terminal cytoplasmic regions. The immune 
epitope of IA-2 is localized exclusively in the cytoplasmic region of IA-2 where its PTP 
(protein-tyrosine-phosphate)-like domain is the main recognition site for auto-Abs. The fact 
that the dominant T cell epitope of IA-2, also localized in the PTP-like region, is structurally 
similar to the VP7 region (VP7 is a major immunogenic protein of rotaviruses) provides 
additional evidence for the crucial role of the molecular mimicry mechanism in the 
pathogenesis of T1D. 
IA-2ǃ (also known as fogrin, PTP-NP, ICAAR and IAR) is structurally similar to IA-2. Its 
intracellular and extracellular domains are structurally identical (by 74 and 26%, 
respectively) to IA-2. IA-2ǃ is predominantly localized in secretory vesicles of beta and some 
other neuroendocrine cells. Anti-IA-2ǃ Abs are present in nearly 50% of patients with newly 
diagnosed T1D; their emergence is usually recorded several years before the appearance of 
the first clinical manifestations of the disease.  
AutoAbs against the insulin antigen are detected in 70–90% of individuals as early as 10 – 12 
years before the clinical stage of T1D. 
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Auto-Ab titer 10-year risk  (% ± SE) HR (95% CI) P 
I quartile   20 ± 14 1*  
II quartile   74 ± 15 6.0 (1.6–22.4) 0.008 
III quartile   84 ± 10 5.9 (1.7–21.1) 0.006 
IV quartile   71 ± 15 4.8 (1.3–17.9) 0.02 
Likelihood of developing diabetes depending on combination of epitope-specific IA-2 
antibodies 
 
IA-2ab 
Epitope combination 
   n (T1D cases) 10-year risk 
IA-2ǃ PTP JM   
+ + + 13 (8) 81%
+ + − 12 (10) 100%
+ − + 1 (1) 
+ − − 4 (3) 
− + + 8 (3) 34%
− + − 10 (4) 44%
− − + 9 (2) 41%
− − − 4 (1)  
For IA-2 antibodies, IA-2ǃ refers to epitopes found in the PTP region of IA-2ǃ and IA-2, PTP 
refers to epitopes found in the PTP region of IA-2 (but not IA-2ǃ), while JM refers to 
epitopes within the IA-2 juxtamembrane region in amino acids 601–682 (combinations with 
no relatives are not shown). (Kordonouri et al., 2010; Kawasaki E et al., 2003; Hanifi-
Moghaddam et al., 2003)  
5.3 ICA  
The target antigen for pancreatic islet cell antibodies has not yet been finally identified. In all 
probability, it represents a heterogeneous cluster of antigens expressed in beta cells. In 
contrast to IA-2ab, ICA is a polyclonal antibody able to interact with all populations of islet 
cells (ǂ, ǃ, Ǆ, ǅ, PP) and other auto-antigens (sialoglucoconjugate, GAD, IA-2A, etc.).  
Antibodies to islet cells are found in 85-90% of patients with onset T1D (cf. 0.5% in 
unaffected individuals) during the very first week after clinical diagnosis. Four weeks 
thereafter, their incidence does not exceed 50%. In patients with one-year history of T1D, 
antibodies to beta cells are present in only 10-20% of cases. 
Similar to other cell-related Abs, ICA does not play any crucial role in beta cell degradation, 
but is one of key markers of cell-mediated autoimmunity. Its detection in blood serum 
suggests latent autoimmune diabetes (LADA) and slow degradation of beta cells.The 
prognostic capacity of ICA is neither high, nor low and is usually manifested 12 years prior 
to T1D development. Its incidence at the clinical diagnosis stage varies from 60 to 80%. 
Correlation between antibody titers and risks for T1D over a period of 7 years. (Achenbach 
et al., 2004; Williams et al., 2002)  
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5.4 IAA - AutoAbs to insulin 
Insulin is a peptide hormone produced by beta cells of pancreatic Langerhans islets. The 
main physiological role of insulin consists in reducing glucose levels in the blood; its 
absolute deficiency is the main cause of T1D.Anti-insulin Abs are indispensable constituent 
elements of blood sera of healthy individuals where their concentrations vary from 1 to 5 
μg/ml. In patients with T1D, serum concentrations of anti-insulin autoAb IgG class can 
reach very high levels. 
Insulin antibodies are associated with many autoimmune pathologies including Graves’ 
disease (40%), Hashimoto’s disease (autoimmune thyroiditis) (20%), Addison’s disease 
(40%), chronic hepatitis (36%), systemic lupus erythematosus (29%), etc. 
Insulin-binding Ab are always present in the blood sera of insulin-treated patients. In 
patients with T1D, the therapeutic effect of insulin diminishes gradually with emergence of 
anti-insulin antibodies, especially after prolonged insulin therapy or administration of high 
daily doses of the hormone. Other factors, e.g., dosage form or purity of the hormonal 
preparation, also play a role. 
Seroconversion of insulin ABS is usually recorded as early as eight years before the onset 
and clinical diagnosis of T1D. However, after this period high antibody titers begin to 
decrease gradually up to the moment of their complete elimination and are detected in only 
30–60% of patients. 
 
Auto-Ab titers 10-year risk  (% ± SE) HR (95% CI) P 
I quartile 45 ± 16 1*  
II quartile   30 ± 13 0.7 (0.2–2.4) 0.55 
III quartile   38 ± 17 0.8 (0.2–2.7) 0.68 
IV quartile   77 ± 12 3.0 (1.1–8.1) 0.03 
(Catherine Pihoker et al., 2005; Heli et al., 2009)  
6. Metabolome as applicable to T1D management at subclinical stages to 
prevent or minimize the imbalance 
In a recent study, a comparison of blood sera from children with type 1 diabetes (T1D), non 
diabetic children and children without autoimmune antibodies revealed metabolic 
disturbances (significant reduction of serum levels of succinate, phosphatidylcholine, 
phospholipin and ketoleucine, drastic elevation of glutamate, etc.) in the T1D group. , 
(Bougnères et al., 2008) The true reason for these disturbances is difficult to establish, since 
all these changes can be associated, with an equal degree of probability, with asymptomatic 
damage of liver and body musculature, T1D, metabolic imbalance caused by environmental 
factors, etc.  
High lysophosphatidylcholine levels are detected in patients’ blood as early as several years 
before the first clinical manifestations of T1D. It should be noted, however, that the 
aforecited studies were performed on children, but not on adults with T1D; therefore, their 
clinical significance is ambiguous.  
Notable elevation of blood sera levels of glutamate potentiates the activity of GAD65, the 
major autoimmune antigen for autoAbs. The figure below shows the dynamics of the 
“glutamine–GABA–GADA“ sequence. As can be seen, neither GADA and IAA, nor unlimited 
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elevation of glutamine and moderate elevation of GABA take place in the initial steps. 
However, in the course of time the concentration of glutamic acid begins to decrease, while 
that of GABA increases; however, autoAbs are not generated even under these conditions. 
Subsequent decreases of glutamic acid and GABA are noted only against the background of 
increasing titers of anti-GAD65 and anti-insulin autoAbs (seroconversion). After T1D passes to 
the clinical diagnosis stage, auto-Abs titers begin to decrease gradually to a nearly 
undetectable level (this widely occurring phenomenon usually lasts 10 to 20 years).  
 
 
Fig. 6. The dynamics of changes in the concentrations of Glu / GABA / GADA and insulin 
Abs in the period between the commencement of the effect of the irreversible diabetes-
inducing factor and first clinical manifestations of T1D. There is a clear seroconversion 
sequence Glu / GABA / GADA with a period of about 1 year. By the moment of appearance 
of first clinical manifestations, some antibodies detected several years theretofore, may be 
missing. (Noteworthy, each individual case may be different from the average). 
There is evidence that in addition to the aforesaid metabolites T1D is characterized by 
fluctuations in the levels of succinic acid, phosphatidylcholine (even in newborns), 
triglycerides and phospholipids.  
7. Environmental factors triggering T1D 
Estimation of the role of environmental factors in triggering one or another pathology and 
development of adequate approaches to diagnosis within maximally short intervals of time 
is one of currently central problems in preclinical medicine. Here, it is necessary to draw a 
demarcation line between autoimmune disorders and background events in order to select 
optimal diagnostic procedures and reliable criteria, since clinical tests do not always provide 
unfailing results that are crucial for diagnosis. Therefore, development of strict elaborate 
protocols is of vital importance for identification and analysis of environmental factors. 
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Continuous exposure to hazardous effects of environmental factors and large-scale 
application of chemical substances in food industry, pharmaceutics and other sectors of 
national economy are harmful for human immune system, since all of them trigger 
pathological reactions resulting in diabetes. Furthermore, uncontrolled intake of drugs and 
frequent viral and bacterial infections form predisposition to allergic reactions and provoke 
autoagression and development of various immune disorders.  
8. Phase 2 characteristics  
8.1 Viral infections as triggering factors in type 1 diabetes 
The large body of evidence (serological, epidemiological, biological, etc.) obtained thus far 
testifies to the ability of certain viruses to provoke type 1 diabetes mellitus (T1D) in human 
beings. Among the immense diversity of other disease-provoking factors, enteroviruses, 
retroviruses, reoviruses, parotiditis viruses, cytomegalovirus, Epstein-Barr virus and a 
clinical variant of the diabetogenic encephalomyocarditis virus are the most likely 
candidates for T1D-triggering factors. 
Viral infections provoke diabetes by operating at different regulatory levels, e.g., by 
disregulating immune mechanisms, by stimulating the activity of pathological systems or by 
interfering with the normal course of regulatory processes occurring in the organism.  
The risks of viral infection and T1D development correlate with the functional stability of 
the organism and its genetic and immune backgrounds. It is well known that morbidity 
from seasonal (especially, in the winter period) virus-borne infections correlates with very 
high incidence of autoimmune diseases including T1D. The reason is in shorter (in 
comparison with summertime) duration of the daylight period and, as a consequence, low 
level of vitamin D synthesis and increased morbidity from viral infections and autoimmune 
disorders. Additional support in favor of this hypothesis can be derived from much greater 
incidence of T1D in North European countries in comparison with Southern Europe.  
8.2 Bacterial infections as triggering factors of T1D 
Recent advances in immunologic research and numerous animal and human model studies 
shed new light on the role of enteric bacteria in triggering autoimmune reactions. It was 
shown, in particular, that certain bacteria (e.g., Bacteroides ovatus) induce diabetes in young 
children predisposed to T1D. The mechanisms whereby bacterial agents interfere with 
immune homeostasis and provoke diabetes are still poorly understood; it is known, 
however, that intestinal bacteria trigger autoimmune responses that initiate destructive 
insulitis. The strongest argument in favor of this viewpoint is an ever increasing (by 20% in 
comparison with control) number of affected individuals infected with sporadic variants of 
these bacteria. The extent of bacterial infection is especially apparent in young children 
whose autoimmune microbiome is the least stable and diversified. Continuous 
sophistication and diversification of the microbiome with ageing point to the decreasing role 
of bacteria in initiating diabetes in adult individuals. (Giongo et al., 2010)  
8.3 Nutritional factors  
For quite a long period of time, viruses were considered to be the only etiogenic external 
factors in T1D. Today, there is evidence that nutritional factors also play a role in T1D 
development. Although the pathogenetic mechanisms of the disease are not yet completely 
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understood, the role of T1D as one of the most essential links in the human immune system 
leaves no doubt, particularly with regard to its tolerance to food antigens. 
As a rule, tolerance to food antigens largely depends on peculiarities of local immune 
reactions whose functional role consists in suppression of immune responses formed under 
the influence of several factors, viz., (i) oral tolerance, (ii) controlled chronic inflammation 
(so-called "physiological inflammation") and (iii) local secretion of IgA.  
Disturbances in the coordinated functioning of these mechanisms stimulate the appearance 
of characteristic manifestations of food allergy. Measurements of blood plasma levels of Abs 
against various food antigens in patients with clinically confirmed T1D revealed high titers 
of IgA and IgG against cow’s milk Ags (bovine serum albumin, BSA), beta lactoglobulin, 
BLG) and some other food Ags, e.g., ovalbumin, OVA. It should be noted, however, that in 
this particular case we deal with the so-called abuse tolerance, which can hardly be 
compared to food allergies associated with high levels of circulating IgE. (Kohno et al., 2002; 
Luopajärvi et al., 2008)  
8.3.1 Nitrosamines  
There is a statistic association between nitrosamines and diabetes as can be judged from 
some biochemical data on destructive effects of nitrosamines on pancreatic Langerhans islet 
beta cells. In a statistical study, nitrosamine levels were determined in foods consumed by 
children under 14 at risk of diabetes. It was found that in children with low dietary 
nitrosamine levels the Odds Ratio (OR) was equal to 1.0 (cf. 1.7 OR and 2.6 OR in children 
with medium and high levels of dietary nitrosamine). (Dahlquist et al., 1990)  
Statistic analysis established a correlation between the quality and quantity of consumed 
food, on the one hand, and susceptibility for diabetes, on the other hand. However, this 
correlation is purely statistical, since biological, biochemical and immunological 
mechanisms responsible for this phenomenon demand further investigation and analysis. 
(Essien & Akpan, 2006)  
8.4 Age  
The growing tendency in the past decades is towards higher incidence of T1D in young people 
and children. In the first place, this is due to negative influences of environmental factors. The 
first peak of T1D is normally observed between the 4th and 6th years of life; the second peak is 
associated with hormonal transformations in the pubertal period (10–12 years).  
On the other hand, there exists a special form of diabetes termed as latent autoimmune 
diabetes in adults (above 30) (LADA). Its most characteristic features are moderate clinical 
manifestations and slow progression of the autoimmune process. The finding that 6% of 
patients with LADA carry protective haplotypes responsible for more slow progression and 
less severe (in comparison with IDDM1) manifestations of the disease indicates that LADA 
appears to be a more widespread form of diabetes than its classical form, viz., T1D. This and 
the aforementioned data emphasize the need for elaborating novel effective criteria and 
approaches to treatment of patients with diagnosed LADA. (Bermúdez et al., 2010)   
8.5 Gender 
Analysis of sex steroids revealed that clinical manifestations of many autoimmune diseases 
vary widely depending on the hormonal status of the organism, e.g., menstrual cycle, 
administration of oral contraceptives, etc. Pregnancy should also be included in this list. The 
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alternative hypothesis states that higher X-linked genetic predisposition of females to 
autoimmune diseases is a result of unbalanced X chromosome inactivation. The X-
inactivation skew theory was recently corroborated for dermatosclerosis and autoimmune 
thyroiditis. Yet another possible mechanism is small-scale exchange of cells between mother 
and fetus pregnancy.  
At the same time, the current views on the role of environmental factors in T1D are often 
diametrally opposite and many practitioners in medicine are inclined to think that the 
stably increasing incidence of this severe autoimmune disease is unrelated to external 
factors. For example, a mass-scale retrospective investigation was carried out in Saudi 
Arabia in the period between 1980–2009. In this study, 119 patients with T1D were 
divided into six groups depending on early clinical manifestations of the disease. There 
was no correlation between the impact of environmental factors and the incidence of T1D 
over a period of three decades.  
9. Medicaments as potential T1D inducers  
For many decades, it was believed that certain chemical substances including patented 
medicaments are harmful for the pancreas and provoke T1D. The mechanisms whereby 
chemical drugs exert their hazardous effects vary widely and are not clearly understood. 
Active drug components accumulated in body cells slow down the functional processes in 
different body tissues and organs and trigger pathological reactions, e.g., by providing 
tropism of certain pathogens or restructuring the systemic architectonics of body organs 
including the pancreas. The presence, in such active components, of sequestered or cryptic 
epitopes provokes negative phenomena, such as molecular mimicry. Not infrequently, 
medicinal drugs trigger a series of immunoregulatory and immunoeffector shifts, which 
culminate in immune disorders including autoimmune destruction of the pancreas.  
10. T1D and vaccination: Is there a correlation between them? The role of 
passive immunization in T1D development  
There exist quite a few hypotheses concerning the role of vaccination in triggering 
autoimmune diseases including T1D. This fact notwithstanding, only few instances proved 
to display a clearcut correlation between vaccination and development of autoimmune 
syndromes. (Ethan Rubinstein, 2004) In the meantime, heated discussions about association 
between autoimmune disorders and vaccination do not abate. Advocates of the 
“autoimmunization” hypothesis refer to recent flagrant global-scale spreading of 
autoimmune diseases with a particular on responsibility of children’s vaccines 
manufacturers. (Classen JB & Classen DC, 1999)  
There is evidence that T1D indeed develop in response to immunization. At the same time, 
in newborn infants vaccinated at the age of several months the incidence of T1D did not 
exceed the morbidity level in children immunized with a single vaccinating dose at the age 
of 2 years. (Karvonen et al., 1999) Mass-scale serial investigations carried out in the USA did 
not establish any associativity between these two events. Similarly, studies into the role of 
vaccination and vaccination timing as risk factors in childhood diabetes failed to establish a 
correlation between vaccination and the risk for autoimmune diseases. (DeStefano et al., 
2001; Blom et al., 2001)  
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11. Associativity between T1D and autoimmune diseases. Polyglandular 
autoimmune syndromes 
T1D is often concomitant with local or systemic autoimmune disturbances, which further 
progress to complex autoimmune diseases or polyglandular syndromes via the cross-
reactivity mechanism. By illustration, in many patients T1D is associated with autoimmune 
thyroiditis (24.5%/autoAbs vs 47.5%), celiac disease (1.4%/autoAbs to gliadin and IgA to 
tissue transglutaminase vs 18.7%), MS (0.5-2%/autoAbs vs 7%), Addison’s disease 
(1.4%/adrenal cortex autoAbs vs 0.7%), autoimmune gastritis (6.9-7.2%/parietal cell 
autoAbs vs 20.9%), etc. (Somers et al., 2009; Villano et al., 2009; De Block et al., 2006)  
Secondary autoimmune disorders associated with later steps of T1D have a number of 
specific features. Thus, autoimmune thyroiditis (AIT) (autoimmune polyglandular 
syndrome 3A version (APS3Av)) is diagnosed in 12-15% of T1D patients; its clinical 
manifestations correlate positively with age, gender (AIT is more frequent in females (8.6%) 
than in males (3.4%)), duration of T1D (mean age of AIT patients varies between 5 and 15 
years), serum levels of the thyroid-stimulating hormone (TSH), etc. Both diseases have a 
common familial hereditary background, but can also be present in a single individual 
suggesting a crucial role of genetic predisposition in the development of polyglandular 
syndromes. Furthermore, high incidence of AIT among first-degree relatives of T1D patients 
points to a significant contribution of genetic factors to immune system failures (see above). 
(Severinski et al., 2003; Hunger-Battefeld et al., 2009)  
Noteworthy, the predominant form of AIT in patients of both sexes is hypothyroidism 
(8.1%), but in males with anti-thyroid Abs AIT is prevalent (85.7% vs 37.5% in females). the 
total incidence of hypothyroidism in T1D patients with anti-thyroid Abs is 52.2%. The 
interval between the onset of T1D and the appearance of first clinical manifestations of AIT 
varies from one year to 5–6 years, while the first thyroid autoAbs appear in the period 
between 6 months and 5–3 years before the onset of the disease. Blood sera of patients with 
APS3Av (AIT and T1D) (Hunger-Battefeld et al., 2009) contain circulating anti-thyroid 
peroxidase and anti-thyroglobulin Abs emerging soon after emergence of GADA (10% and 
8% of cases, respectively); more than 6% of such patients contain both types of autoAbs. As 
mentioned earlier in this chapter, MS is also associated with T1D. In this case, morbidity 
from MS among male patients exceeds that in females nearly fourfold (2% vs. 0.5%). 
According to statistic reports, non-diabetic sisters run five times higher risks for MS than 
other cohorts of the general population. Consequently, adult females with T1D can be 
assigned to the highest risk group for associated autoimmune disorders (e.g., MS). (Bussone 
et al., 2009; Otto-Buczkowska et al., 2009)  
The association between T1D and RA is not so apparent as in the case of T1D and MS. In 
depth studies established that about 13% of patients whose first-degree relatives suffer from 
T1D have clinical signs of RA. According to other authors, no such linkage does not exist. 
(Hakala et al., 1992)  
Based on these findings, we can state with assurance that T1D increases the risk for 
autoimmune disorders through triggering the formation of autoimmune clusters and 
polyglandular autoimmune syndromes. As a rule, circulating autoAbs begin to appear in 
the blood serum as early as several years before the development of severe secondary 
disorders and absolute clinical manifestations of the disease. The genetic data provide the 
physician with a broad spectrum of autoimmune diseases that are likely to develop in 
patients with T1D. Time-lapse monitoring of patients’ blood sera not only affords reliable 
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dynamic control over disease progression, but also enables the physician to estimate the 
efficiency of ongoing therapy, to search for early-stage biomarkers for diagnosing secondary 
autoimmune disorders and, last but not least, to implement adequate preventive and 
curative treatment.  
12. Multiple Sclerosis (MS) 
12.1 State-of-art models of multiple sclerosis 
Multiple sclerosis (MS), a remitting and relapsing autoimmune disease of the central 
nervous system (CNS), represents a generalized degenerative inflammatory process. Its 
main causative factors are demyelination, degradation of oligodendrocytes and 
degeneration of axons.  
The clinical course of MS includes three stages, viz., the preclinical stage, the autoimmune 
inflammation stage and the neurodegeneration stage. Some basically important targets 
(including gene-oriented ones) emerging in the course of MS evolution can be used in the 
design of novel preclinical diagnostic tools. Expression of gene products including 
functionally important transcripts is currently employed in the design of proteomes. The use 
of these constructs (commonly referred to as diagnostic microchips) as early as at the 
preclinical pathology stage allows multifarious manipulations with specific targets in the 
course of immune attacks. Impaired structure of the myelin sheath (demyelination) and 
degradation of axons take place at the very earliest stages of preclinical MS, i.e., long before 
the clinical onset of the disease. This generates a need for innovative preclinical diagnosis 
protocols and, in a more distant perspective, preventive treatment of MS. In this context, 
genetic tests acquire special importance as valuable analytical tools for predicting and 
estimating risks in MS. In terms of present-day classifications, the genes supporting 
predisposition to MS are divided into three main groups, viz., immune system genes (DRB1, 
OPN, CD44, CD24, CCR5-Δ32), myelin metabolism genes (MBP, CTLA4, ICAM1) and 
cytokins (TGFǃ1, TNF). AutoAbs to the basic protein of myelin are amont the key 
autoaggression markers for demyelination-related pathologies. Some of these Abs have 
functional resources of their own, e.g., proteolytic activity towards the Ag substrate. The 
dynamics of Abs spectra in patients with MS reflect etiogenic peculiarities of MS evolution. 
It is now well established that pre-early stages of MS are accompanied by the appearance of 
specific Abs against two categories of determinants, viz., mimicking and myelin epitopes. 
After termination of the preclinical phase, serum titers of mimicking Abs show a tendency 
to decrease, while those of antimyelin and antineural autoAbs increase in contrast. This 
upward trend points to escalation of antitissue autoaggression and formation of a typical 
clinical picture of the disease including a complete set of clinical and serological criterial 
features of PIFAS. Early emergence and long persistence of antimyelin autoAbs in MS 
patients points to a correlation between serum positivity and duration of the disease. 
(Sepiashvili et al., 2010; Martynov et al., 2010) 
13. Aortic aneurisms 
Aortic aneurisms (AA) are related to the category of socially important diseases involving a 
high risk for lethality. Its main causal factors are degradation of elastin (e.g., by proteases), 
pronounced structural changes in medial smooth muscle cells (SMC), aortic vasculature 
atrophies and formation of the preclinical pathological syndrome. The main clinically 
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important causes of AA established thus far can be presented as follows: (i) genetic 
predisposition and hereditary diseases affecting the molecular architectonics of connective 
tissue (e. g. Marfan’s syndrome); (ii) atherosclerosis and arterial hypertension. Very often, AA 
is associated with atherosclerosis, especially, in patients of senior age groups. Male gender, 
smoking, carriage of specific infectious pathogens (herpes simplex virus, cytomegalovirus, Chl. 
pneumonia, syphilis and tuberculosis pathogens) also play a role in the pathogenesis of AA.  
Long duration of the preclinical stage (aortal dilation to the critical level) in patients with AA 
provides the physician with a unique opportunity to break the pathogenetic linkage and 
thus to arrest the further progression of the disease on going from the preclinical to the 
clinical stage.  
It is more expedient to perform preclinical screening in three steps in full conformity with 
prenosological diagnostic protocols. (i) identification of blood serum levels of biomarkers in 
the form of so-called serodiagnostic packages (matrix metalloproteinases (MMP), cystatin С, 
osteoprotegerin (OPG), soluble fractions of elastin (SFE) and heavy chains of myosin 
(HCM), antibodies against Ch. pneumonia, CMV and HSV). These biomarkers are used as 
diagnostic package components and allow maximally accurate diagnosis and, which is no 
less important, estimation of lesion size even at the preclinical stage; (ii) MRT or contrasting 
CT scanning angiography for identifying exact location of dilated vessels, viz., topological 
sites in the vascular network responsible for hypersecretion of specific biomarkers; (iii) 
biopsy of the dilated portion of the aorta containing a suspected aneurism followed by 
morphological, immunogenetic and molecular-biological testing of bioptats. This procedure 
is highly invasive and its implementation is not recommended in the absence of positive 
results in the first two steps. If the dilated portion of the aorta cannot be visualized directly 
and the first-step tests give positive results, screening for biomarkers must be repeated after 
a period of several months. If positive results are obtained from serological doublet tests, 
MRT or CT angiography must be conducted to the required extent.  
Early (preclinical) diagnosis holds especially great promise being the most efficient step in 
prophylactic and preventive treatment of AA. The uniqueness and high therapeutic 
potentials of preclinical diagnosis combined with low invasiveness of the nonsurgical 
approach and design, on its basis, of more advanced diagnostic protocols opens up fresh 
opportunities for the development of rationalized and practicable innovative technologies as 
a breakthrough in cardio- and angiosurgery. Prospective analysis of clinical utility of 
targeted therapy as a tool for preventive (preoperative) treatment and/or postsurgical 
angiorehabilitation will also make the subject of future investigations. 
14. Rheumatic diseases 
In considering the role of pathogenetic factors in rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE) and ankylosing spondylitis (AS), special emphasis should be laid on 
risk genes and the extent to which they overlap. 
According to GWA data, the contribution of MHC to RA risk can approximately be 
estimated as 30%, HLA-DRB1 alleles (e.g., DRB1*0401 with OR of 3) being critical for RA. 
Additional loci essential for estimating RA risks were identified by high-density genotyping 
as HLA-DP in patients with anticyclic citrullinated peptide antibodies, (HLA-
DR2(DRB1*1501)) and DR3 (DRB1*0301) alleles in the MHC class II region with Ors of 2, risk 
variants in the MHC class III cluster encoding the TNF gene and the C2 complement 
components C4A and C4B.  
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Other loci in the MHC class III region associated with SLE include: the SKIV2L gene 
encoding the superkiller viralicidic activity of a 2-like protein, the PTPN22 gene, TNFAIP3 
and TRAF1-C5 loci (TNF-associated signalling pathway genes), Integrin-ǂ-M (ITGAM), 
STAT4, IL23R and a number of other genes.  
15. Conclusion 
In-depth studies into pathogenesis and etiogenesis of autoimmune diseases and discovery 
of reliable biomarkers for diagnosing various pathological conditions provide a way for 
predicting, with a sufficiently high degree of probability, the risk of relapses and 
exacerbations and possible clinical manifestations of the disease. In its turn, considerable 
recent progress in medical science (in medical genetics, bionanomedicine and 
bioinformatics, in particular) provides a clue to the design of advanced protocols for 
preclinical screening of patients. The construction of individual genetic maps with special 
reference to familial predispositions and time-lapse monitoring of risk groups for 
pathomorphological markers have one common goal, viz., to collect information for early 
implementation of preventive and therapeutic intervention strategies. Moreover, dynamic 
control over functional activities of different body organs and tissues on the basis of well 
established and validated proteomic and metabolomic data enables early prediction of 
exacerbations and complications and implementation of preventive therapy. The latter is 
based on the use of state-of-art pharmacological protocols and, if surgical correction is 
required, of the most recent advances in transplantation and regenerative medicine.  
Considerable improvement and wide-scale application of preclinical diagnosis algorithms 
and preventive treatment protocols for routine clinical application are among the most 
topical problems in today’s medical practice. More urgent strategies are aimed at 
compensating structural and functional deficiencies of damaged organs and fragments 
thereof. In genetic studies combined with early detection of minor lesion foci and analysis of 
immune, proteomic and metabolomic disturbances open up new vistas for social welfare 
with the ultimate goal to improve current standards of public health care at large. 
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